TW200602060A - Combination comprising an active ingredient which decreases the activity of the epidermal growth factor (EGF) and an epothilone derivative - Google Patents
Combination comprising an active ingredient which decreases the activity of the epidermal growth factor (EGF) and an epothilone derivativeInfo
- Publication number
- TW200602060A TW200602060A TW094130192A TW94130192A TW200602060A TW 200602060 A TW200602060 A TW 200602060A TW 094130192 A TW094130192 A TW 094130192A TW 94130192 A TW94130192 A TW 94130192A TW 200602060 A TW200602060 A TW 200602060A
- Authority
- TW
- Taiwan
- Prior art keywords
- combination
- growth factor
- egf
- decreases
- activity
- Prior art date
Links
- 239000004480 active ingredient Substances 0.000 title abstract 2
- 230000007423 decrease Effects 0.000 title abstract 2
- 230000000694 effects Effects 0.000 title abstract 2
- 150000003883 epothilone derivatives Chemical class 0.000 title abstract 2
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 title abstract 2
- 102000010780 Platelet-Derived Growth Factor Human genes 0.000 abstract 2
- 108010038512 Platelet-Derived Growth Factor Proteins 0.000 abstract 2
- 125000000217 alkyl group Chemical group 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 229910052739 hydrogen Inorganic materials 0.000 abstract 2
- 239000001257 hydrogen Substances 0.000 abstract 2
- 230000002062 proliferating effect Effects 0.000 abstract 2
- 229940126062 Compound A Drugs 0.000 abstract 1
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 abstract 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 239000003937 drug carrier Substances 0.000 abstract 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 229940124617 receptor tyrosine kinase inhibitor Drugs 0.000 abstract 1
- 230000019491 signal transduction Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
Abstract
The invention relates to a combination which comprises (a) a signal transduction inhibitor selected from a PDQF (platelet-derived growth factor) receptor tyrosine kinase inhibitor and an active ingredient which decreases the activity of the epidermal growth factor (EGF) and (b) an epothilone derivative of formula I, , in which compound A represents O or NRN, wherein RN is hydrogen or lower alkyl, R is hydrogen or lower alkyl, and Z is O or a bond, and optionally at least one pharmaceutically acceptable carrier for simultaneous, separate or sequential use, in particular, for the delay of progression or treatment of a proliferative disease; a pharmaceutical composition comprising such a combination; the use of such a combination for the preparation of a medicament for the delay of progression or treatment of a proliferative disease; a commercial package comprising such a combination as a combined preparation; and to a method of treatment of a warm-blooded animal.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0104840.4A GB0104840D0 (en) | 2001-02-27 | 2001-02-27 | Use of organic compounds |
| US33904001P | 2001-10-30 | 2001-10-30 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| TW200602060A true TW200602060A (en) | 2006-01-16 |
| TWI343258B TWI343258B (en) | 2011-06-11 |
Family
ID=9909622
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW091103305A TWI303170B (en) | 2001-02-27 | 2002-02-25 | Combination comprising a platelet-derived growth factor(pdgf) receptor tyrosine kinase inhibitor and an epothilone derivative |
| TW094130192A TWI343258B (en) | 2001-02-27 | 2002-02-25 | Combination comprising an active ingredient which decreases the activity of the epidermal growth factor (egf) and an epothilone derivative |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW091103305A TWI303170B (en) | 2001-02-27 | 2002-02-25 | Combination comprising a platelet-derived growth factor(pdgf) receptor tyrosine kinase inhibitor and an epothilone derivative |
Country Status (5)
| Country | Link |
|---|---|
| CZ (1) | CZ20032277A3 (en) |
| GB (1) | GB0104840D0 (en) |
| HU (1) | HUP0303333A3 (en) |
| TW (2) | TWI303170B (en) |
| ZA (1) | ZA200306404B (en) |
-
2001
- 2001-02-27 GB GBGB0104840.4A patent/GB0104840D0/en not_active Ceased
-
2002
- 2002-02-25 TW TW091103305A patent/TWI303170B/en not_active IP Right Cessation
- 2002-02-25 TW TW094130192A patent/TWI343258B/en not_active IP Right Cessation
- 2002-02-26 CZ CZ20032277A patent/CZ20032277A3/en unknown
- 2002-02-26 HU HU0303333A patent/HUP0303333A3/en unknown
-
2003
- 2003-08-18 ZA ZA200306404A patent/ZA200306404B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| ZA200306404B (en) | 2004-06-07 |
| CZ20032277A3 (en) | 2004-01-14 |
| HUP0303333A2 (en) | 2004-01-28 |
| HUP0303333A3 (en) | 2004-05-28 |
| GB0104840D0 (en) | 2001-04-18 |
| TWI303170B (en) | 2008-11-21 |
| TWI343258B (en) | 2011-06-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2002223684A1 (en) | Combination comprising an agent decreasing vegf activity and an agent decreasing egf activity | |
| WO2004009784A3 (en) | Novel inhibitors of kinases | |
| WO2002067941A3 (en) | Combination comprising a signal transduction inhibitor and an epothilone derivative | |
| WO2003042172A3 (en) | C-5 modified indazolylpyrrolotriazines | |
| EP1725536B8 (en) | Imidazoline derivatives having cb1-antagonistic activity | |
| BG104544A (en) | Novel acylguanadine derivatives as inhibitors of bone resorption and as vitronectin receptor antagonists | |
| WO2004001059A3 (en) | Heterocyclic inhibitors of kinases | |
| IL149150A0 (en) | 2-(4-(6-methoxy-naphthalene-2-yl)-5-pyridin-4-yl-1h-imidazole-2-yl)-2-methyl-derivatives, pharmaceutical compositions comprising them and use thereof as tie2 receptor kinase inhibitors | |
| WO2001087846A3 (en) | Tricyclic pyrazole derivatives as protein kinase inhibitors | |
| WO2002080846A3 (en) | Epothilone derivatives and methods for making and using the same | |
| GB0112348D0 (en) | Compounds | |
| GB0102672D0 (en) | Compounds | |
| WO2002048148A3 (en) | Pyrazolopyridine derivatives | |
| BG106044A (en) | Substituted 1,4-dihydroindeno[1,2-c]pyrazoles as inhibitors of tyrosine kinase | |
| MXPA04000567A (en) | Combinations comprising epothilones and pharmaceutical uses thereof. | |
| WO2001000617A3 (en) | Novel piperazinylalkylthiopyrimidine derivatives, pharmaceutical compositions containing the same, and a process for the preparation of the same | |
| WO2003054001A3 (en) | Method for preparing echinocandin derivatives and their compositions | |
| WO2002024665A8 (en) | Arylalkane-sulfonamides having endothelin-antagonist activity | |
| WO2003051838A3 (en) | Protein kinase inhibitors | |
| TW200602060A (en) | Combination comprising an active ingredient which decreases the activity of the epidermal growth factor (EGF) and an epothilone derivative | |
| AU2002248531A1 (en) | Pyrazolopyriadine derivatives | |
| WO2004044174A3 (en) | Topoisomerase-targeting agents | |
| CA2534833A1 (en) | Bicyclo[3.1.1]heptane substituted benzimidazolone and quinazoli-none derivatives as agonists on human orl1 receptors | |
| WO2002092565A3 (en) | 3-aminoalkyl-2-aryl-indole derivatives and their use as gnrh antagonists | |
| WO2002018363A3 (en) | 3-phenyl-propanoic acid derivatives as protein tyrosine phosphatase inhibitors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM4A | Annulment or lapse of patent due to non-payment of fees |